Actively Recruiting
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
Led by Kingman Regional Medical Center · Updated on 2024-05-23
50
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
Sponsors
K
Kingman Regional Medical Center
Lead Sponsor
L
La Jolla Pharmaceutical Company
Collaborating Sponsor
AI-Summary
What this Trial Is About
Norepinephrine is a catecholamine that is the first-line vasopressor for septic shock. The addition of non-catecholamine vasopressors, including vasopressin and angiotensin-II may be used in adults with septic shock that have inadequate mean arterial pressure while on norepinephrine. Uncertainty exists regarding the timing of initiation of these agents and there is a lack of data comparing their safety and efficacy. The current literature suggests that earlier initiation of angiotensin-II will have a more significant reduction on norepinephrine-equivalent dose compared to later initiation. In addition, approximately half of patients initiated on vasopressin do not have an early hemodynamic response 6 hours after initiation. The purpose of this study is to evaluate the efficacy of angiotensin-II when used as the second vasopressor agent for septic shock.
CONDITIONS
Official Title
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Admitted to ICU within 12 hours of emergency department presentation for septic shock
- Septic shock defined by infection with two or more systemic inflammatory response syndrome criteria
- Mean arterial pressure less than 65 mm Hg despite fluid resuscitation requiring vasopressor support
- Serum lactate greater than 2 mmol/L
- Receiving norepinephrine at 15-25 mcg/min
You will not qualify if you...
- Age less than 18 years
- Pregnancy or lactation
- Known allergy to angiotensin-II or hydrocortisone sodium succinate
- Requiring more than 25 mcg/min norepinephrine or other vasopressors at study start
- Significant bleeding preventing use of chemical prophylaxis for blood clots
- Treatment with another investigational drug or intervention during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kingman Regional Medical Center
Kingman, Arizona, United States, 86401
Actively Recruiting
Research Team
T
Tyson Dietrich, PharmD
CONTACT
A
Anthony Santarelli, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here